Markets:

Overview

News

Currencies

International

Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

64.12 -1.07 (-1.64%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

The 3 Best Biotech Stocks to Buy in May 2024 ↗

May 09, 2024

If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.

Via InvestorPlace

When you look at NASDAQ:HALO, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

May 08, 2024

When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗

May 07, 2024

HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Expert Ratings For Halozyme Therapeutics ↗

May 07, 2024

Via Benzinga

PTC Therapeutics Stock Sees IBD RS Rating Climb To 72 ↗

May 01, 2024

PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72.

Via Investor's Business Daily

Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout. ↗

April 30, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO): a strong growth stock preparing for the next leg up?.

Via Chartmill

NASDAQ:HALO is not too expensive for the growth it is showing. ↗

April 23, 2024

NASDAQ:HALO stands out as a growth opportunity that won't break the bank.

Via Chartmill

9 Analysts Have This To Say About Halozyme Therapeutics ↗

April 16, 2024

Via Benzinga

NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout. ↗

April 05, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout.

Via Chartmill

Sarepta Therapeutics Stock Shows Improved Technical Strength ↗

April 29, 2024

The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73.

Via Investor's Business Daily

3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition ↗

April 25, 2024

Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now.

Via InvestorPlace

Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents. ↗

April 16, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.

Via Chartmill

Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket ↗

April 09, 2024

Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results.

Via Benzinga

In the world of growth stocks, NASDAQ:HALO shines as a value proposition. ↗

April 02, 2024

While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.

Via Chartmill

NASDAQ:HALO, a strong growth stock, setting up for a breakout. ↗

February 21, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) qualifies as a high growth stock and is consolidating.

Via Chartmill

Breaking Down Halozyme Therapeutics: 7 Analysts Share Their Views ↗

February 21, 2024

Via Benzinga

Halozyme Therapeutics: Q4 Earnings Insights ↗

February 20, 2024

Via Benzinga

The 3 Best Biotech Stocks to Buy in Q2 2024 ↗

March 29, 2024

Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2.

Via InvestorPlace

Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark ↗

March 18, 2024

On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.

Via Investor's Business Daily

Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

March 14, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move.

Via Chartmill

7 Biotech Stocks to Buy as Sector Rotation Ramps Up ↗

March 13, 2024

With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.

Via InvestorPlace

Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation. ↗

March 11, 2024

While growth is established for HALOZYME THERAPEUTICS INC (NASDAQ:HALO), the stock's valuation remains reasonable.

Via Chartmill

Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

March 01, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO), an undervalued stock with good fundamentals.

Via Chartmill

Earnings Preview: Halozyme Therapeutics ↗

February 19, 2024

Via Benzinga

Looking for growth without the hefty price tag? Consider NASDAQ:HALO. ↗

February 19, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) stands out as a growth opportunity that won't break the bank.

Via Chartmill

NASDAQ:HALO, an undervalued stock with good fundamentals. ↗

February 09, 2024

Despite its impressive fundamentals, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains undervalued.

Via Chartmill

Earnings Scheduled For February 20, 2024 ↗

February 20, 2024

Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion.

Via Benzinga

Gates Ventures, Mayo Clinic Back Tiny Robot Created By $400M Apple Face ID Inventors To Treat Brain Disease ↗

February 15, 2024

Michael Shpigelmacher, Founder and CEO of Bionaut Labs, with the company’s micro-robot designed to swim through the central nervous system into the brain to treat disease now on trial in the U.S.

Via Benzinga

NASDAQ:HALO, a strong growth stock, setting up for a breakout. ↗

January 31, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move.

Via Chartmill

Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients ↗

January 29, 2024

Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.